Alvotech (HAM:Z45) Total Operating Expense: €228.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Z45 Alvotech HAM:Z45
48 GF Score
Price €2.95
GF Value €16.65
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Total Operating Expense?

Alvotech HAM:Z45 +8.06% 48 Total Operating Expense is €228.6 Mil as of Mar. 2026. GuruFocus rates HAM:Z45 with a GF Score™ of 48/100 and a GF Value™ of €16.65 (Possible Value Trap). The stock has 7 warning signs investors should review.

Alvotech's Total Operating Expense for the three months ended in Mar. 2026 was €43.3 Mil. Alvotech's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €228.6 Mil.

Alvotech Total Operating Expense Related Terms

Alvotech Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Alvotech's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Total Operating Expense Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 240.92 344.92 261.75 224.17 232.76

Alvotech Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.48 70.54 65.97 48.71 43.34
HAM:Z45
48GF Score
Alvotech HAM:Z45
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €228.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €228.6 Mil mean?
Alvotech (HAM:Z45) has a Total Operating Expense of €228.6 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alvotech and its competitors.
Is Alvotech's Total Operating Expense too high?
Alvotech's current Total Operating Expense is €228.6 Mil. Overall, Alvotech has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Total Operating Expense compare to PAHC and COLL?
Alvotech's Total Operating Expense of €228.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alvotech and its competitors. Alvotech's current Total Operating Expense is €228.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €16.65, compared to a current price of €2.95 — trading 82.3% below its estimated fair value. The current Total Operating Expense is €228.6 Mil. Alvotech's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current Total Operating Expense is €228.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (HAM:Z45) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of €2.95 is trading 82.3% below its estimated GF Value™ of €16.65. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for HAM:Z45:

  • Total Operating Expense: €228.6 Mil
  • GF Value™: €16.65 vs. price of €2.95 (82.3% below fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAALVO:Iceland
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
48GF Score

Get the complete analysis for HAM:Z45

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.95
Price
€16.65
GF Value